Open AccessEarly Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads
Author(s) -
Michael H. Gelb,
Frederick S. Buckner
Publication year - 2021
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.1c00091
Subject(s) - malaria , drug discovery , farnesyltransferase , neglected tropical diseases , drug , drug development , clinical trial , tropical disease , medicine , disease , african trypanosomiasis , intensive care medicine , pharmacology , trypanosomiasis , biology , immunology , bioinformatics , pathology , prenylation , biochemistry , enzyme
In this Viewpoint, we provide a brief description of two efforts to develop drugs to treat diseases caused by tropical parasites (Malaria, human African trypanosomiasis and Chagas disease). These efforts are largely based in a University setting but draw heavily on Pharma for a complete progression from drug hit discovery to advancement toward clinical trials. The first case is the development of protein farnesyltransferase inhibitors, and the second case is a series of benzthiazoles, the target of which is being investigated.